Compare CTSO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | ALLR |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 19.3M |
| IPO Year | 2008 | 2021 |
| Metric | CTSO | ALLR |
|---|---|---|
| Price | $4.52 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 136.5K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,503,908.00 | $320,000.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $16.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.30 | $0.77 |
| 52 Week High | $7.44 | $1.84 |
| Indicator | CTSO | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 38.05 |
| Support Level | $2.88 | N/A |
| Resistance Level | $7.20 | $1.45 |
| Average True Range (ATR) | 0.79 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 15.43 | 3.70 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.